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Journal  and were based largely on evidence in the G
for Chronic Obstructive Lung Dise se (GOLD).3 Si
Australian Lung Foundation has updated COPDX, 
more recently published evidence and systematic r
Cochrane Library. Levels of evidence have been recla
summary in accordance with guidelines from the N
and Medical Research Council (NHMRC).4342 MJA • Volume 184 NumABSTRACT
• Long-acting β2 agonists are an effective and convenient 
treatment for chronic obstructive pulmonary disease (COPD), 
but do not significantly improve lung function.
• The long-acting anticholinergic tiotropium, which can be taken 
once daily, decreases exertional dyspnoea and increases 
endurance by reducing hyperinflation.
• The role in COPD of the combination of a long-acting β2 
agonist and a glucocorticoid in a single inhaler remains unclear.
• The minimum duration of an effective pulmonary rehabilitation 
program that includes exercise training is 6 weeks.
• Long-term treatment with inhaled glucocorticoids may reduce 
the rate of decline in lung function, but the effect is small.
• Aminophylline should no longer be routinely used in acute 
exacerbations of COPD.
• Non-invasive positive pressure ventilation (NPPV) reduces 
mortality and hospital stay in patients with acute hypercapnic 
ventilatory failure; it is also an effective weaning strategy for 
patients who require intubation.
• Further studies are required to clarify the role of NPPV in the 
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long-term management of stable COPD.hro
pu
thaC nic obstructive pulmonary disease (COPD) is a majorblic health problem. It is the single leading cause of deatht is continuing to increase and is now the third largest
contributor to the burden of disease in Australia.1 In response to this
challenge, the Australian Lung Foundation and Thoracic Society of
Australia and New Zealand developed clinical practice guidelines
(COPDX) to improve the diagnosis and management of COPD.







C: Confirm diagnosis and assess severity
Spirometry remains the mainstay of diagnosis of COPD, but is
underutilised in Australia. Trials are currently underway to explore
barriers to the use of spirometry in general practice, to develop
simple reliable questionnaires that may guide general practitioners
in screening patients for referral, and to confirm that more wide-
spread application improves outcomes in chronic respiratory dis-
eases. A diagnostic algorithm is under evaluation on the Australian
Lung Foundation website (http://www.lungnet.org.au) (Box 1).
O: Optimise function (Box 2)
Therapeutics
Long-acting β2 agonists: Regular treatment with long-acting β2
agonists is more effective and convenient than treatment with
short-acting bronchodilators (evidence level I) and is associated
with improved quality of life5 (evidence level II). However, a
systematic review of eight randomised controlled trials (RCTs) of
long-acting β2 agonists found no overall difference in forced
expiratory volume in 1 second (FEV1) when compared with
placebo (evidence level I), and only one trial reported less
dyspnoea in patients during treatment with these drugs6 (evidence
level II). As the review excluded patients with > 15% reversibility
after a dose of short-acting β2 agonist, it may underestimate the
benefits of long-acting  β2 agonists in unselected COPD patients.
Tiotropium: This inhaled anticholinergic agent has a duration of
effect longer than 24 hours, and so can be taken once daily.7
Compared with placebo and regular ipratropium, tiotropium
reduces exacerbations and improves quality of life.8 It also
decreases exertional dyspnoea and increases endurance by reduc-
ing hyperinflation9 (evidence level II).
Combination inhalers: Combinations of an inhaled glucocorticoid
and long-acting β2 agonist in a single inhaler are being increasingly
used in COPD. A systematic review of six RCTs of combination
inhalers for COPD concluded that, compared with placebo, com-
bination therapy led to clinically meaningful differences in quality
of life, symptoms and frequency of exacerbations10 (evidence level
I). However, comparison of the different combination therapies
with their single components gave conflicting results, possibly
because of differential drop-out rates in the original studies
(Professor Paul Jones, St Georges Hospital, London, personal
communication). Again, patients with > 12% and 200 mL bron-
chodilator reversibility were excluded from four of the six trials in
this review, potentially reducing the benefits that might be seen in
a more general population with COPD. Firmer conclusions about
the effects of combination therapy in a single inhaler require more
data, including comparison with the effects of the two drugs
administered separately in double-dummy trials.
Oral glucocorticoids: The use of oral glucocorticoids in stable
COPD was recently examined in a systematic review of 24 RCTs.11
Overall, it would be necessary to treat seven patients (95% CI, 5–
12) with oral steroids to achieve one extra case of an increase in
FEV1 greater than 20%. There was no evidence to support the
long-term use of oral steroids at daily doses less than 10–15 mg
prednisolone, although some evidence that higher doses
( 30 mg) improved lung function over a short period. Potentially
harmful adverse effects would prevent us recommending long-
term use at these high doses in most patients (evidence level I).
Avoid osteoporosis
In younger patients with asthma or mild COPD, there is no evidence
of an effect of inhaled glucocorticoids in daily doses of 1000 μg or less
of fluticasone or equivalent given for 2–3 years on bone mineralber 7 • 3 April 2006
CLINICAL UPDATEdensity (BMD) or vertebral fractures12 (evidence level I). Higher
doses are associated with biochemical markers of increased bone
turnover, but data on BMD and fractures at these doses are not yet
available. In older people, the BMD and fracture safety profile of most
inhaled glucocorticoids for the treatment of COPD is not known.
However, triamcinolone was associated with reduced BMD in the
Lung Health Study13 (evidence level II). Australian guidelines have
been published on the prevention and treatment of osteoporosis,
including glucocorticoid-induced osteoporosis.14
Improve function
Non-invasive positive pressure ventilation: Although 12 to 24-
month studies in patients with stable COPD with chronic respiratory
failure have suggested that the addition of non-invasive positive
pressure ventilation (NPPV) may have some beneficial effects,15,16 its
widespread use cannot yet be advocated.17 Compared with long-
term oxygen therapy alone, the addition of NPPV has some beneficial
effects on CO2 retention and shortness of breath.
16 A well powered
RCT is near completion in Australia, evaluating NPPV use in COPD
patients with hypercapnia.
Pulmonary rehabilitation: This reduces dyspnoea, anxiety and
depression, improves exercise capacity and quality of life, and may
reduce hospitalisation (evidence level I). The minimum duration of an
effective rehabilitation program that includes exercise training is 6
weeks; the longer the program continues, the more effective it appears
to be18-20 (evidence level II). However, as yet, effective structures that
maintain benefit have not been subjected to robust clinical trials.21
Anabolic steroids and nutritional supplements: In patients with
COPD and weight loss, anabolic steroids may increase body weight
and lean body mass, but have little or no effect on exercise
capacity22,23 (evidence level II). Although
weight loss and low body mass index are both
poor prognostic indicators in COPD, there is
level I evidence that nutritional supplementa-
tion does not alter anthropometric measures,
lung function or exercise capacity when nutri-
tion is already depleted.24
Opioids: These may have a role in the relief of
severe intractable dyspnoea25,26 (evidence level I).
P: Prevent deterioration (Box 2)
Risk factor reduction
The mainstay for preventing deterioration in
COPD is complete cessation of smoking, as
only complete cessation slows decline in lung
function.27 A combination of psychosocial
and pharmacological interventions is supe-
rior to no treatment or psychosocial interven-
tions alone for achieving smoking cessation28
(evidence level I).
Vaccinations
Recommended vaccinations in COPDX have
been harmonised with NHMRC approved
guidelines (http://immunise.health.gov.au/
handbook.htm). In addition, there is some
evidence of a possible benefit from Haemo-
philus influenzae vaccination. Six RCTs of
oral killed non-typable H. influenzae vaccine found a significant
reduction in the incidence of bronchitic episodes 3 months after
vaccination, but the effect had disappeared by 9 months.29 The
severity of exacerbations in the treatment group, as measured by
the requirement to prescribe antibiotics, was reduced by 65% at 6
months (evidence level I). However, a larger clinical trial is needed
to assess longer term prognosis, and the vaccine is not currently
available. Another systematic review of 13, mostly low-quality,
trials of oral lyophilised bacterial extracts in COPD found some
evidence of symptomatic improvement, but no convincing reduc-
tion in exacerbations30 (evidence level I).
1 Diagnostic algorithm to distinguish chronic obstructive pulmonary disease 
(COPD) from asthma
The patient’s age, height, sex and spirometry results are entered in the left column. A brief 
questionnaire is completed in the right hand column. The program calculates predicted values and 
severity, and provides a likely diagnosis. (Available at: http://www.lungnet.org.au.) ◆
2 Therapies to optimise function and prevent 
deterioration in chronic obstructive pulmonary disease
Established efficacy Supported by new evidence
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The effect of inhaled glucocorticoids on decline in lung function is
controversial. Systematic reviews and meta-analyses of the availa-
ble RCTs have found a small benefit of uncertain significance when
compared with placebo (evidence level I). A 2003 meta-analysis
found a combined difference in the rate of decline in FEV1 of
5.0 mL/year between treatment groups (95% CI, −1.2 to 11.2 mL/
year),31 while a second meta-analysis in the same year found a
combined difference of 7.7 mL/year (95% CI, 1.3–14.2 mL/year).32
The varying conclusions of these reviews would not lead to a
recommendation for inhaled glucocorticoids to be used routinely
in all patients with COPD. However, these drugs are indicated for
patients with a previously documented response and for those who
have severe COPD with frequent exacerbations (evidence level II).
Mucolytic agents
Mucolytic agents may reduce the frequency and duration of
exacerbations (evidence level I). A systematic review concluded
that, in patients with COPD or chronic bronchitis who have a
higher than average rate of exacerbations, treatment with muco-
lytic agents was associated with a small but significant reduction in
acute exacerbations and total days of disability.33 However, a recent
large RCT of N-acetylcysteine did not confirm an overall reduction
in exacerbations, although a significant reduction was still seen in
the subgroup who were not having concomitant treatment with
inhaled steroids34 (evidence level II). Nonetheless, such agents are
not available for COPD through the Pharmaceutical Benefits
Scheme (PBS) or Repatriation PBS, and are thus currently not
widely used in Australia.
D: Develop a support network and self-management plan
Patients should be encouraged to take appropriate responsibility
for their own management (evidence level III-1). However, a
systematic review of self-management plans in COPD found no
effect on hospital admissions, emergency department visits, days
lost from work or lung function.35 Inconclusive results were
observed for health-related quality of life, COPD symptoms and
use of other health care resources. Clearly, further well designed
RCTs with sufficiently long follow-up are required. Nonetheless,
self-management education reduced the need for rescue medica-
tion and led to increased use of oral steroids and antibiotics for
respiratory symptoms (evidence level I).
X: manage eXacerbations
Hospital in the home: Up to a quarter of carefully selected patients
presenting to hospital emergency departments with acute exacer-
bations of COPD can be safely and successfully treated at home
with support from respiratory nurses. A systematic review of seven
RCTs of “hospital in the home” schemes found no significant
differences in readmission rates or mortality, and a preference for
these schemes by patients and carers36 (evidence level I). However,
further research is needed, as the studies reviewed were small and
varied in the interventions used.
Nebulised β 2 agonists and anticholinergics: Hospital manage-
ment of a severe exacerbation of COPD usually includes nebulised
β2 agonist, administered continuously in extremely unwell
patients and intermittently in others. An anticholinergic agent
may be delivered together with the nebulised β2 agonist in
patients with severe exacerbations or when response to the β2
agonist alone is poor. However, a systematic review that included
four RCTs did not demonstrate any additional benefit on FEV1 of
combining an anticholinergic compared with β2 agonists alone37
(evidence level I).
Aminophylline: The routine use of intravenous aminophylline is
no longer recommended for acute exacerbations of COPD (evi-
dence level I). A systematic review of four RCTs of methylxan-
thines found only a transient increase of 101 mL in FEV1 after 3
days, with a 4.6-fold increased risk of nausea and vomiting.38 This
is confirmed by a recent RCT in patients with non-acidotic acute
exacerbations, which found no clinically useful reductions in
breathlessness or length of hospital stay and no improvement in
lung function, but significantly more nausea among those treated
with aminophylline.39
Antibiotic therapy: Exacerbations with clinical signs of infection
benefit from antibiotic therapy. A recent multicentre RCT found
that moxifloxacin was equivalent to standard antibiotics (amoxy-
cillin, clarithromycin or cefuroxime) for clinical success, and
superior for clinical cure and bacteriological eradication, and
reduced the frequency of exacerbations over the following 5
months.40 These findings applied to patients with milder COPD,
most of whom were not prescribed oral steroids (evidence level II).
Non-invasive positive pressure ventilation: NPPV is effective for
managing acute hypercapnic ventilatory failure in COPD (evidence
level I). A systematic review of 14 RCTs found that NPPV resulted
in significantly decreased mortality, decreased need for endotra-
cheal intubation, and more rapid improvement in arterial blood
gases.41 Length of hospital stay was reduced by a mean of 3.2 days.
When intubation is required, weaning from ventilation is facili-
tated by NPPV. A systematic review of five RCTs found that the
NPPV-weaning strategy was associated with significantly lower
mortality and reduced length of hospital stay by a mean of 7.3
days.42
Conclusion
The evidence base for safe and effective management of COPD
continues to improve, although there is still a need for well
designed RCTs, particularly of non-pharmacological interventions.
Further evidence from RCTs and systematic reviews needs to be
couched in terms of meaningful outcomes and should provide the
numbers needed to treat for benefit and harm. It also needs to be
remembered that absence of evidence for a treatment effect is not
the same as evidence for absence of an effect. The challenge for the
Australian Lung Foundation and the Thoracic Society of Australia
and New Zealand is to disseminate COPDX efficiently and to
improve the diagnosis and management of COPD in Australia. The
most recent approved full version of the guidelines is available at
<http://www.copdx.org.au>.
Acknowledgements
The Australian Lung Foundation supported meetings of authors and prepa-
ration of this article. We also wish to thank the other members of the COPD
Evaluation Committee, Nicholas Glasgow, Susan Jenkins and Richard Wood-
Baker, for their helpful comments.344 MJA • Volume 184 Number 7 • 3 April 2006
CLINICAL UPDATECompeting interests
Michael Abramson has served on the scientific advisory committee for the
Australian Asthma Study, which was sponsored by GlaxoSmithKline, and received
travel assistance from AstraZeneca on one occasion.
Alan Crockett has received fees from several pharmaceutical companies for
providing training in spirometry for general practitioners and practice nurses.
Peter Frith has received honoraria from Boehringer Ingelheim, Pfizer, GlaxoSmith-
Kline and AstraZeneca for delivering lectures and workshops to general practition-
ers on the use of COPDX, and a grant-in-aid from AltanaPharma for travel to the
Thoracic Society of Australia and New Zealand annual scientific meeting.
Christine McDonald has received honoraria for speaking at meetings sponsored
by Boehringer Ingelheim, Pfizer, GlaxoSmithKline and AstraZeneca, and travel
assistance from these companies to attend international respiratory meetings.
Author details
Michael J Abramson, PhD, FRACP, FAFPHM, Professor of Clinical 
Epidemiology and Deputy Head1
Alan J Crockett, PSM, PhD, FANZSRS, Director, Primary Care 
Respiratory Unit2
Peter A Frith, MD, FRACP, Head of Southern Respiratory Services3
Christine F McDonald, PhD, FRACP, Deputy Director4
1 Department of Epidemiology and Preventive Medicine, Monash 
University, Melbourne, VIC.
2 Discipline of General Practice, University of Adelaide, Adelaide, SA.
3 Respiratory Department, Repatriation General Hospital, Adelaide, SA.




1 Mathers C, Vos T, Stevenson C. The burden of disease and injury in Australia:
summary report. Canberra: Australian Institute of Health and Welfare, 1999.
2 McKenzie DK, Frith PA, Burdon JGW, Town GI. The COPDX Plan: Australian
and New Zealand guidelines for the management of chronic obstructive
pulmonary disease 2003. Med J Aust 2003; 178 (6 Suppl): S1-S40. 
3 Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis,
management, and prevention of chronic obstructive pulmonary disease.
NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD)
Workshop Summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
4 National Health and Medical Research Council. A guide to the development,
implementation and evaluation of clinical practice guidelines. Canberra:
NHMRC, 1999. Available at: http://www.nhmrc.gov.au/publications/synopses/
cp30syn.htm (accessed Jan 2006).
5 Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus
ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir
Crit Care Med 2001; 164: 778-784.
6 Appleton S, Poole P, Smith B, et al. Long-acting beta2-agonists for chronic
obstructive pulmonary disease patients with poorly reversible airflow limitation.
Cochrane Database Syst Rev 2001; 4: CD001104.
7 Casuburi R, Mahler DA, Jones PW, et al. A long term evaluation of once-daily
inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;
19: 217-224.
8 Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in
patients with COPD during 1 year’s treatment with tiotropium. Eur Respir J
2002; 19: 209-216.
9 O’Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinfla-
tion, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 825-831.
10 Nannini L, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and longact-
ing beta-agonist in one inhaler for chronic obstructive pulmonary disease.
Cochrane Database Syst Rev 2004; 3: CD003794.
11 Walters JA, Walters EH, Wood-Baker R. Oral corticosteroids for stable chronic
obstructive pulmonary disease. Cochrane Database Syst Rev 2005; 3:
CD005374.
12 Jones A, Fay JK, Burr M, et al. Inhaled corticosteroid effects on bone
metabolism in asthma and mild chronic obstructive pulmonary disease.
Cochrane Database Syst Rev 2002; 1: CD003537.
13 Lung Health Study Research Group. Effect of inhaled triamcinolone on the
decline in pulmonary function in chronic obstructive pulmonary disease. N Engl
J Med 2000; 343: 1902-1909.
14 Sambrook PN, Seeman E, Phillips SR, Ebeling PR. Preventing osteoporosis:
outcomes of the Australian Fracture Prevention Summit. Med J Aust 2002; 176
(8 Suppl): 1-16. 
15 Casanova F, Celli BR, Tost L, et al. Long-term controlled trial of nocturnal nasal
positive pressure ventilation in patients with severe COPD. Chest 2000; 118:
1582-1590.
16 Clini E, Sturani C, Rossi A, et al. The Italian multicentre study on non-invasive
ventilation in chronic obstructive pulmonary disease patients. Eur Respir J
2002; 20: 529-538.
17 Elliott MW. Noninvasive ventilation in chronic ventilatory failure due to chronic
obstructive pulmonary disease. Eur Respir J 2002; 20: 511-514.
18 Griffiths TL, Burr ML, Campbell IA, et al. Results at 1 year of outpatient
multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lan-
cet 2000; 355: 362-368.
19 Finnerty JP, Keeping I, Bullough I, et al. The effectiveness of outpatient
pulmonary rehabilitation in chronic lung disease; a randomised controlled trial.
Chest 2001; 119: 1705-1710.
20 Green RH, Singh SJ, Williams J, et al. A randomised controlled trial of four
weeks versus seven weeks of pulmonary rehabilitation in chronic obstructive
pulmonary disease. Thorax 2001; 56: 143-145.
21 Ries AL, Kaplan RM, Myers R, et al. Maintenance after pulmonary rehabilitation
in chronic lung disease: a randomised trial. Am J Respir Crit Care Med 2003;
167: 880-888.
22 Yeh SS, DeGuzman B, Kramer T, et al. Reversal of COPD-associated weight loss
using the anabolic agent oxandrolone. Chest 2002; 122: 421-428.
23 Weisberg J, Wanger J, Olson J, et al. Megestrol acetate stimulates weight gain
and ventilation in underweight COPD patients. Chest 2002; 121: 1070-1078.
24 Ferreira IM, Brooks D, Lacasse Y, et al. Nutritional supplementation for stable
chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; 2:
CD000998.
25 Jennings A-L, Davies AN, Higgins JPT, et al. A systematic review of the use of
opioids in the management of dyspnoea. Thorax 2002; 57: 939-944.
26 Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo
controlled crossover trial of sustained release morphine for the management of
refractory dyspnoea. BMJ 2003; 327: 523-528.
27 Simmons MS, Connett JE, Nides MA, et al. Smoking reduction and the rate of
decline in FEV1: results from the Lung Health Study. Eur Respir J 2005; 25: 1011-
1017.
28 van der Meer RM, Wagena EJ, Ostelo RW, et al. Smoking cessation for chronic
obstructive pulmonary disease. Cochrane Database Syst Rev 2001; 1:
CD002999.
29 Foxwell AR, Cripps AW, Dear KBG. Haemophilus influenzae oral whole cell
vaccination for preventing acute exacerbations of chronic bronchitis. Cochrane
Database Syst Rev 2003; 3: CD001958.
30 Steurer-Stey C, Bachmann LM, Steurer J, et al. Oral purified bacterial extracts in
chronic bronchitis and COPD: systematic review. Chest 2004; 126: 1645-1655.
31 Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticoster-
oids on FEV1 in patients with chronic obstructive pulmonary disease: a meta
analysis. Ann Intern Med 2003; 138: 969-973.
32 Sutherland ER, Allmers H, Ayas NT, et al. Inhaled corticosteroids reduce the
progression of airflow limitation in chronic obstructive pulmonary disease: a
meta-analysis. Thorax 2003; 58: 937-941.
33 Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstruc-
tive pulmonary disease. Cochrane Database Syst Rev 2003; 1: CD001287.
34 Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-
acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchi-
tis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-
controlled trial. Lancet 2005; 365: 1552-1560.
35 Monninkhof EM, van der Valk PD, van der Palen J, et al. Self-management
education for chronic obstructive pulmonary disease. Cochrane Database Syst
Rev 2002; 4: CD002990.
36 Ram FSF, Wedzicha JA, Wright J, et al. Hospital at home for acute exacerba-
tions of chronic obstructive pulmonary disease. Cochrane Database Syst Rev
2003; 4: CD003573.
37 McCrory DC, Brown CD. Anti-cholinergic bronchodilators versus beta2-sym-
pathomimetic agents for acute exacerbations of chronic obstructive pulmonary
disease. Cochrane Database Syst Rev 2003; 1: CD003900.
38 Barr RG, Rowe BH, Camargo CAJ. Methylxanthines for exacerbations of
chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003; 2:
CD002168.
39 Duffy N, Walker P, Diamantea F, et al. Intravenous aminophylline in patients
admitted to hospital wih exacerbations of chronic obstructive pulmonary
disease: a prospective randomised controlled trial. Thorax 2005; 60: 713-717.
40 Wilson R, Allegra L, Huchon G, et al. Short-term and long-term outcomes of
moxifloxacin compared with standard antibiotic treatment in acute exacerba-
tions of chronic bronchitis. Chest 2004; 125: 953-964.
41 Ram FSF, Picot J, Lightowler J, et al. Non-invasive positive pressure ventilation
for treatment of respiratory failure due to exacerbations of chronic obstructive
pulmonary disease. Cochrane Database Syst Rev 2004; 3: CD004104.
42 Burns KEA, Adhikari NKJ, Meade MO. Noninvasive positive pressure ventila-
tion as a weaning strategy for intubated adults with respiratory failure.
Cochrane Database Syst Rev 2003; 4: CD004127.
(Received 1 Sep 2005, accepted 19 Dec 2005) ❏MJA • Volume 184 Number 7 • 3 April 2006 345
